In the News
ADA updates medical care standards for diabetes
Areas of the standards that were changed include classifying type 1 diabetes, setting thresholds for metabolic surgery, and emphasizing lifestyle management.
ACP releases updated guideline on oral pharmacologic treatment of type 2 diabetes
ACP recommended that clinicians prescribe metformin for type 2 diabetes when pharmacologic therapy is needed to improve glycemic control in a strong recommendation based on moderate-quality evidence.
Supplemental triglyceride-lowering therapy may lower CVD risk in statin-treated patients with diabetic dyslipidemia, study finds
The rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes was 27% lower in participants with dyslipidemia randomized to fenofibrate than among those randomized to placebo.
MKSAP quiz: Altered mental status with anorexia and vomiting
This month's quiz asks readers to evaluate a 74-year-old woman with several hours of altered mental status who developed anorexia 3 days ago and vomiting 2 days ago.
Metformin use associated with improved outcomes in patients with historical contraindications
A systematic review found that metformin appeared to be associated with lower all-cause mortality in patients with moderate chronic kidney disease, congestive heart failure, or chronic liver disease with hepatic impairment.
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis
The study authors concluded that the negative effects observed would limit clinical use of liraglutide in patients with type 1 diabetes.
Physician volume linked to diabetes care quality, study finds
The researchers found that higher ambulatory volume overall was associated with lower rates of appropriate eye exams, HbA1c testing, and LDL cholesterol testing, but higher diabetes-specific volume was associated with better care according to quality indicators.
Continuous glucose monitoring system approved to direct therapy, but daily fingersticks still needed
The G5 Mobile Continuous Glucose Monitoring System is now approved for patients and clinicians to use results directly from the device to make diabetes treatment decisions.
Spotlight on pioglitazone
Evidence on possible risks of pioglitazone, including bladder cancer, prostate cancer, and fractures, made the news in the past month.